pfizer data and persuasive...
David Weaver
..argument to be presented for the 9/20 date set for widespread booster deployment
(they're looking for authorization to boost anyone 6 months out from shot #2)
The basic conclusion:
* side effect profile worse than shot 2 (about a factor of 3, though they don't state it as plainly), but effects resolve
* they excluded anyone with previous covid, but if you read between the lines, such individuals would be a problem because they'd show antibody levels that would make the results less favorable
* the group is very small (relatively) given the expected deployment (the sample group is a little over 300 individuals)
* the sample group excluded anyone over 55 (why?), but they concluded that information could be extrapolated to individuals over 55. Exclusion of the part of the population who would benefit most is odd, but a guess at this point would be that a younger study cohort has less chance of serious adverse reactions that couldn't be attributed to something else.
It's a little puzzling why they wouldn't focus more on outcomes rather than measures that aren't outcomes, but their job is to put together a convincing data set, and we'll get outcomes data from israel soon enough.
I expect that CDC will recommend widespread boosters after this is presented (if we're betting at lloyds, we'll hear that there were some dissenting opinions but overall the CDC makes a definitive conclusion - especially since the dissenting opinions aren't at the top of the food chain on this one).
Likely conclusion for someone on the sideline (see your doctor if you don't like mine) - expect a greater chance of some pain from side effects, but also likely that covid chance of catching and hospitalization should be less after the boost (especially if you've never had covid previously).
The statistics for prevention of both against delta trail those gleaned from the retrospective study in israel for individuals who had any vaccine plus real covid, but the trick is still that you have to have real covid (which I'm OK with after vax, but I understand why others may not be).
Moderna states that they have good data showing less effectiveness for the original test group vs. those who weren't in the test group (or as they described it, those 13 months out from vaccination vs. about
.
I am puzzled, though, why something that stands to generate about $15B in revenue couldn't study more than 300 individuals, measure actual outcomes, and include the part of the population who stands to benefit the most from the boost.